Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexsero and Prevnar13 coadministration with routine infant vaccines
2016-003268-37Phase 3
- Sponsor
- GSK
- Start
- Sep 2018
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of meningococcal group B vaccine and Prevnar 13 in meningococcal disease and pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Solicited safety adverse events.
02
Drugs
meningococcal group B vaccinePrevnar 13
03
Conditions
meningococcal diseasepneumococcal disease
Beyond the preview
Go deeper on 2016-003268-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003268-37.